Powered by 
Technavio
Aldeyra Therapeutics Inc. | Data-Driven Analysis and Industry Review
Published: August 22, 2024Aldeyra Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for various inflammatory diseases. The company's lead product candidate, ALD-101, is a first-in-class topical ocular formulation designed to inhibit Aldehyde Dehydrogenase 1 (ALDH1) and address the root cause of inflammation in diseases such as dry eye syndrome and allergic conjunctivitis. Aldeyra's proprietary technology platform focuses on the discovery, development, and commercialization of small-molecule inhibitors of ALDH1 for multiple indications. The company's mission is to improve the lives of patients by delivering effective, safe, and convenient therapeutic solutions for debilitating inflammatory conditions.'
1. Aldeyra Therapeutics is a clinical-stage biotech company focused on developing therapeutics for various inflammatory diseases, including ocular and systemic conditions.
2. The company's lead product candidate, ALD-101, is a first-in-class, topical, small-molecule inhibitor of the Resolvin E1 metabolizing enzyme 15-lipoxygenase-15-LOX. It is being developed for the treatment of dry eye disease and other ocular inflammatory conditions.
3. Aldeyra's pipeline also includes ALD-403, an orally administered small molecule inhibitor of 15-LOX, which is being developed for the treatment of systemic inflammatory diseases, such as atopic dermatitis and asthma.
4. The company has entered into partnerships with several pharmaceutical and biotech companies to advance its research and development programs. For instance, it has a collaboration with Merck KGaA to develop and commercialize ALD-101 for ocular indications outside of North America.
5. Aldeyra Therapeutics has a strong intellectual property position, with multiple patents issued or pending in the US and other countries, protecting its proprietary technology and product candidates.
1. Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapeutics for immune-mediated diseases and lysosomal storage disorders.
2. The company leverages its proprietary technology platform, Aldeyra Lysosomal Targeting Technology (ALTT), to design small molecule drugs that target specific lysosomal enzymes and receptors.
3. Aldeyra's lead product candidate, ALD1910, is a potent and selective inhibitor of the enzyme dipeptidyl peptidase 1 (DP1), which is overexpressed in various immune-mediated diseases.
4. The company's pipeline includes multiple programs in development for various indications, including allergic conjunctivitis, atopic dermatitis, and lysosomal storage disorders such as Fabry disease.
5. Aldeyra has a collaborative partnership with the National Institutes of Health (NIH) to develop ALD1910 for the treatment of Fabry disease, and has received Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) for this indication.
Browse Our Research Portfolio In Aldeyra Therapeutics Inc. Markets
Health Care
Pharmaceuticals
Health Care Providers and Services
Pharmaceuticals
Health Care Services
About Technavio
With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.
